Pacira BioSciences (PCRX) Total Debt (2016 - 2025)
Historic Total Debt for Pacira BioSciences (PCRX) over the last 15 years, with Q3 2025 value amounting to $376.7 million.
- Pacira BioSciences' Total Debt rose 2211.77% to $376.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $376.7 million, marking a year-over-year increase of 2211.77%. This contributed to the annual value of $585.3 million for FY2024, which is 37263.15% up from last year.
- According to the latest figures from Q3 2025, Pacira BioSciences' Total Debt is $376.7 million, which was up 2211.77% from $300.2 million recorded in Q2 2025.
- In the past 5 years, Pacira BioSciences' Total Debt ranged from a high of $685.7 million in Q4 2021 and a low of $109.8 million during Q2 2024
- In the last 5 years, Pacira BioSciences' Total Debt had a median value of $284.7 million in 2022 and averaged $277.0 million.
- In the last 5 years, Pacira BioSciences' Total Debt crashed by 6951.96% in 2023 and then skyrocketed by 37263.15% in 2024.
- Over the past 5 years, Pacira BioSciences' Total Debt (Quarter) stood at $685.7 million in 2021, then tumbled by 58.48% to $284.7 million in 2022, then tumbled by 56.5% to $123.8 million in 2023, then skyrocketed by 372.63% to $585.3 million in 2024, then plummeted by 35.64% to $376.7 million in 2025.
- Its Total Debt stands at $376.7 million for Q3 2025, versus $300.2 million for Q2 2025 and $303.6 million for Q1 2025.